Carisma Therapeutics

At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality: • Testing and validating our foundational scientific perspective • Redefining manufacturing • Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform: https://bit.ly/39dHRwm

Exciting News! Our CT-0508 Phase 1 trial results are published today in Nature Medicine. This first-in-human CAR-Macrophage trial for heavily pre-treated metastatic HER2+ solid tumors validates the CAR-M mechanism, showing anti-tumor activity, TME remodeling, and induction of anti-tumor immunity along with a favorable safety profile. Building on this progress, we are advancing CT-1119, our next-gen anti-Mesothelin CAR-monocyte, into a Phase 1 trial for ovarian & pancreatic cancers this year, with data expected 4Q 2025. Check out the full publication below: https://lnkd.in/em3b9Ght

Our President and CEO, Steven Kelly, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 4:40 PM ET. Stay tuned for updates! For full details and webcast information, read our press release: https://lnkd.in/eSnaUZEN #Healthcare #Biotech #Immunotherapy #OppenheimerConference

Pleased to announce the publication of our preclinical work in Nature Communications, showcasing the synergy between CAR-M and PD-1 blockade in solid tumors. Congratulations to lead author Stefano Pierini and the outstanding team at Carisma Therapeutics for their dedication and remarkable contributions to this achievement. Link: https://lnkd.in/eMyeiUcp #Immunotherapy #CARM #Innovation #CarismaTherapeutics

Don’t miss Carisma Therapeutics President & Chief Executive Officer Steven Kelly fireside chat today at the 7th Annual Evercore HealthCONx Conference at 9:35 am ET. The webcast is available on the investor section of our website: https://lnkd.in/eyHna8cV

Happy Thanksgiving from Carisma Therapeutics! This Thanksgiving, we extend our heartfelt gratitude to all who support and inspire our mission to transform immunotherapy. Your trust drives us to innovate and strive for meaningful change in healthcare. May your day be filled with warmth, happiness, and cherished moments with loved ones. Wishing you and your families a joyous and memorable Thanksgiving! #Thanksgiving #Gratitude #Innovation #CarismaTherapeutics

Today we announced that President and CEO Steven Kelly will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on December 5 at 9:35 am ET. For full details and webcast information, read our press release: https://lnkd.in/gPWMqnDc

Today at American Association for the Study of Liver Diseases (AASLD), we shared exciting new preclinical results demonstrating the anti-fibrotic potential of engineered macrophages across multiple fibrosis models. These results underscore the efficacy of our engineered macrophages as a differentiated, off-the-shelf approach for treating advanced liver fibrosis. Read more in our press release: https://lnkd.in/eXFC4bwn #AASLD2024 #LiverFibrosis #CellTherapy #Biotech #Innovation

This #VeteransDay, we honor the brave men and women who have selflessly served in our armed forces. We are deeply grateful for your sacrifice and dedication to protecting our freedom. Thank you for your service. #VeteransDay2024 #ThankYouVeterans #CarismaHonors

Today, we shared new preclinical data on our anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna. This innovative therapy reprograms myeloid cells to precisely target and destroy GPC3+ tumor cells, showing immense potential as an off-the-shelf solution for solid tumors. Learn more: https://lnkd.in/eUCFJZz2 #Immunotherapy #CancerResearch #CellTherapy #HCC #SITC2024 #CarismaTherapeutics